drugset / Trial / NCT05588297
Preoperative Nivolumab Plus Bevacizumab Combined With Chemotherapy Before Surgery in Patients With pMMR/MSS Colorectal Cancer Liver Metastases
NaSingle-groupOpen-labelTreatment
Summary
This prospective, single-arm study aims to investigate the safety and efficacy of Nivolumab plus bevacizumab and chemotherapy as neoadjuvant treatment in pMMR/MSS Colorectal cancer liver metastases patients
Timeline
- Start
- 2022-10
- Primary completion
- 2023-03
- Completion
- 2025-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bevacizumab | Monoclonal antibody | 10 mg/kg | Intravenous |
| Subject | Capecitabine | Small molecule | 1500 mg/m2 | Oral |
| Subject | Nivolumab | Monoclonal antibody | 360 mg | Intravenous |
| Subject | Oxaliplatin | Small molecule | 200 mg/m2 | Intravenous |